Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ecolab Inc. (ECL) vs Mesoblast Limited (MESO) Price & Performance

Ecolab Inc.Trade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Ecolab Inc. vs Mesoblast Limited — how do they compare? Ecolab Inc. trades at $285.5 (market cap $79.73B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Ecolab Inc. is far larger — about 36.9× Mesoblast Limited's market cap, and Ecolab Inc. pays a 1.03% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

ECLMESO
Market Cap
$79.73B$2.16B
Sector
Consumer CyclicalTechnology
52-Week High
$308.35$20.96
52-Week Low
$245.73$12.88
Enterprise Value
$88.51B$2.17B
Dividend Yield
1.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ecolab Inc.

ECL trades at $285.17, up 0.6% today, with a bullish technical signal and strong analyst support. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance. Revenue growth remains steady, with a net income margin of 12.57% and robust cash flow from operations of $2.95B in 2025. Recent news highlights dividend declarations and institutional buying interest.

Outlook is positive with a consensus price target of $327.90, implying 15% upside. Risks include elevated valuation multiples and potential margin pressure from input costs. The stock's momentum is supported by earnings beats and strategic acquisitions, but investors should monitor debt levels and competitive dynamics in the water and hygiene sector.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Ecolab Inc.

Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.

Read more on ECL

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO